FDA grants Fast Track designation to Ionis Pharmaceuticals' zilganersen for treating Alexander disease.

Ionis Pharmaceuticals has been granted Fast Track designation by the FDA for zilganersen, a drug candidate aimed at treating Alexander disease, a rare and fatal neurological disorder with no existing treatments. This designation accelerates the development of medications addressing serious unmet medical needs. The pivotal study for zilganersen has completed enrollment, and top-line data is expected in late 2025, marking a significant advance in potential treatment options.

October 01, 2024
6 Articles